NKGen Biotech (NKGN) Competitors $0.14 +0.01 (+9.43%) As of 08/26/2025 10:21 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKGN vs. FBLG, ENLV, CVKD, TAOX, NAII, RLYB, SONN, QTTB, PASG, and NNVCShould you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include FibroBiologics (FBLG), Enlivex Therapeutics (ENLV), Cadrenal Therapeutics (CVKD), Synaptogenix (TAOX), Natural Alternatives International (NAII), Rallybio (RLYB), Sonnet BioTherapeutics (SONN), Q32 Bio (QTTB), Passage Bio (PASG), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical products" industry. NKGen Biotech vs. Its Competitors FibroBiologics Enlivex Therapeutics Cadrenal Therapeutics Synaptogenix Natural Alternatives International Rallybio Sonnet BioTherapeutics Q32 Bio Passage Bio NanoViricides FibroBiologics (NASDAQ:FBLG) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends. Which has more risk and volatility, FBLG or NKGN? FibroBiologics has a beta of -0.74, indicating that its share price is 174% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Do analysts recommend FBLG or NKGN? FibroBiologics currently has a consensus target price of $13.00, indicating a potential upside of 2,067.39%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in FBLG or NKGN? 76.2% of NKGen Biotech shares are held by institutional investors. 20.0% of FibroBiologics shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor FBLG or NKGN? In the previous week, FibroBiologics had 2 more articles in the media than NKGen Biotech. MarketBeat recorded 2 mentions for FibroBiologics and 0 mentions for NKGen Biotech. FibroBiologics' average media sentiment score of 0.94 beat NKGen Biotech's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the media. Company Overall Sentiment FibroBiologics Positive NKGen Biotech Neutral Which has better valuation & earnings, FBLG or NKGN? FibroBiologics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroBiologicsN/AN/A-$11.16M-$0.36-1.67NKGen BiotechN/AN/A-$82.94M-$2.45-0.06 Is FBLG or NKGN more profitable? NKGen Biotech's return on equity of 0.00% beat FibroBiologics' return on equity.Company Net Margins Return on Equity Return on Assets FibroBiologicsN/A -710.25% -118.02% NKGen Biotech N/A N/A -479.36% SummaryFibroBiologics beats NKGen Biotech on 10 of the 14 factors compared between the two stocks. Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKGN vs. The Competition Export to ExcelMetricNKGen BiotechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$6.52M$283.81M$5.76B$21.26BDividend YieldN/AN/A3.95%3.53%P/E Ratio-0.03N/A30.8029.20Price / SalesN/A598.18467.2153.54Price / CashN/A22.4437.7623.64Price / Book-0.0512.6510.105.36Net Income-$82.94M-$115.81M$3.26B$996.59M7 Day Performance9.43%3.98%2.85%2.99%1 Month Performance-23.68%-2.66%4.02%2.88%1 Year Performance-80.95%-11.20%42.89%12.54% NKGen Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKGNNKGen BiotechN/A$0.15+9.4%N/A-80.7%$6.52MN/A-0.03N/AFBLGFibroBiologics3.0905 of 5 stars$0.61-1.0%$13.00+2,048.8%-65.3%$25.61MN/A-1.6810News CoverageENLVEnlivex Therapeutics3.2166 of 5 stars$1.08flat$10.00+825.9%-12.8%$25.54MN/A-1.6470Upcoming EarningsGap UpCVKDCadrenal Therapeutics3.0734 of 5 stars$13.75+11.6%$32.00+132.7%+76.3%$25.21MN/A-1.554TAOXSynaptogenixN/A$6.96-0.7%N/AN/A$24.44MN/A-0.354Positive NewsNAIINatural Alternatives International1.4465 of 5 stars$3.67-6.9%N/A-36.1%$24.38M$113.80M-2.64290Positive NewsHigh Trading VolumeRLYBRallybio3.0046 of 5 stars$0.60+2.5%$10.00+1,576.2%-52.4%$24.31M$761K-0.6340SONNSonnet BioTherapeutics3.485 of 5 stars$3.61+0.6%$20.00+454.0%-41.6%$24.25M$20K0.0010Positive NewsGap UpQTTBQ32 Bio2.639 of 5 stars$1.82-7.6%$12.17+568.5%-95.5%$24.03M$1.16M-0.4239Positive NewsPASGPassage Bio4.0089 of 5 stars$7.04-5.8%$91.75+1,203.3%-52.6%$23.76MN/A-0.39130Positive NewsGap UpNNVCNanoViricides0.4312 of 5 stars$1.43-3.4%N/A-29.4%$22.98MN/A-1.9920News Coverage Related Companies and Tools Related Companies FibroBiologics Alternatives Enlivex Therapeutics Alternatives Cadrenal Therapeutics Alternatives Synaptogenix Alternatives Natural Alternatives International Alternatives Rallybio Alternatives Sonnet BioTherapeutics Alternatives Q32 Bio Alternatives Passage Bio Alternatives NanoViricides Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NKGN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access